9 recruiting, 7 completed, 4 not yet recruiting, 2 active not recruiting. 12 Phase 2, 6 Phase 1, 3 Phase 3, 1 Not applicable, 1 Phase 4.
Follow Biosimilar Pharmaceuticals: new trials by email Literature Review of Biosimilar Pharmaceuticals trials Research Report on Biosimilar Pharmaceuticals
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adalimumab Dose Adjustment for Pediatric Uveitis Treatment Trial Adalimumab/Biosimilar - Juvenile Idiopathic Arthritis Associated Uveitis, Uveitis, Anterior | Phase 4 | Not yet recruiting | Nisha Acharya | 160 | 2026-09-01 | 2026-07-13 |
| Trastuzumab/Pertuzumab With Fulvestrant and Culmerciclib in HR+/HER2+ Early Breast Cancer Trastuzumab (or biosimilar), Pertuzumab, Culmerciclib - Breast Cancer | Phase 2 | Not yet recruiting | Hebei Medical University Fourth Hospital | 31 | 2026-09-01 | 2026-10-19 |
| Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer Trastuzumab Deruxtecan, Pertuzumab, Taxane Chemotherapy - HER2 + Breast Cancer | Phase 2 | Recruiting | Shanghai Jiao Tong University School of Medicine | 50 | 2026-02-02 | 2026-02-06 |
| Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer QL1706 injection, Trastuzumab (or biosimilar), Pertuzumab (or biosimilar) - Breast Cancer | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 188 | 2025-12-15 | 2025-11-28 |
| Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer Carboplatin, Docetaxel, Trastuzumab (or biosimilar) - Breast Cancer | Phase 2 | Recruiting | University of Kansas Medical Center | 100 | 2025-11-14 | 2026-05-06 |
| First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer ATX-295, ATX-295 and bevacizumab (or biosimilar) - Advanced Solid Tumors, Breast Cancer Recurrent | Phase 1 / Phase 2 | Recruiting | Accent Therapeutics | 218 | 2025-03-21 | 2026-10-13 |
| NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study Olaparib, Bevacizumab, Durvalumab - Ovarian Cancer Stage IV | Phase 2 | Not yet recruiting | British Columbia Cancer Agency | 40 | 2024-11-01 | 2024-10-23 |
| Pharmacokinetic and Pharmacodynamic Effects of Insulex® R in Comparison to Humulin® R in Healthy Subjects Insulex® R (soluble human insulin, biosimilar), Humulin® R (soluble human insulin, biosimilar) - Healthy Subjects | Phase 1 | Completed | Laboratorios Pisa S.A. de C.V. | 40 | 2024-10-24 | 2026-01-23 |
| Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer SHR-A1811, SHR-A1921, SHR-A2009 - Advanced Breast Cancer, Metastatic Breast Cancer | Phase 2 | Recruiting | Fudan University | 160 | 2024-10-21 | 2026-09-03 |
| Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder G-CSF (filgrastim or biosimilar), Apheresis, Plerixafor - RUNX1 Familial Platelet Disorder | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 4 | 2024-05-20 | 2026-06-11 |
| Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer Carboplatin or cisplatin, Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar, Bevacizumab or biosimilar - Recurrent Ovarian Carcinoma | Not applicable | Recruiting | The University of Hong Kong | 18 | 2023-11-01 | 2025-06-11 |
| Siplizumab for Sickle Cell Disease Transplant Siplizumab, Exchange Transfusion, Total Body Irradiation - Anemia, Sickle Cell | Phase 1 / Phase 2 | Terminated | Columbia University | 1 | 2023-09-28 | 2026-06-10 |
| Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura Caplacizumab, Corticosteroids, anti-CD20 antibody - Thrombotic Thrombocytopenic Purpura | Phase 3 | Completed | Sanofi | 51 | 2022-11-21 | 2025-12-30 |
| Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin - Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer | Phase 3 | Recruiting | Genelux Corporation | 186 | 2022-08-31 | 2026-08-26 |
| BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR) BIVV020 (SAR445088), Intravenous immunoglobulin (IVIg), Rituximab or biosimilar - Transplant Rejection | Phase 2 | Active not recruiting | Sanofi | 48 | 2022-06-09 | 2026-08-21 |
| Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer Tucatinib, Pertuzumab, Trastuzumab - Metastatic Breast Cancer With a Isolated Brain Progression | Phase 2 | Active not recruiting | UNICANCER | 53 | 2021-12-17 | 2025-11-17 |
| An Observational Study of Follitropin Alpha Biosimilar: the Real-world Data Follitropin Alfa, Follicle Stimulating Hormone/Luteinizing Hormone - Reproductive Issues, Reproductive Disorder | Completed | IVFarma LLC | 5484 | 2020-01-12 | 2021-10-22 | |
| Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs Biosimilar, Originator (legacy) drug - Rheumatoid Arthritis, Ankylosing Spondylitis | Unknown | McGill University Health Centre/Research Institute of the McGill University Health Centre | 800 | 2018-11-26 | 2020-06-02 | |
| Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers Ubamatamab, Cemiplimab, Sarilumab - Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer | Phase 1 / Phase 2 | Recruiting | Regeneron Pharmaceuticals | 890 | 2018-05-21 | 2026-09-25 |
| Investigating the Utilisation and Effectiveness of Originator and Biosimilar Anti-TNF Agents Originator, Biosimilar - Rheumatoid Arthritis, Psoriatic Arthritis | Unknown | Opal Rheumatology Ltd. | 5000 | 2018-03-01 | 2018-03-21 |
Showing 20 of 25. Sign in to see all of them.
Breast Neoplasms (5) · Ovarian Neoplasms (5) · Arthritis, Rheumatoid (3) · Spondylitis, Ankylosing (3) · Arthritis, Psoriatic (2) · Fallopian Tube Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Anemia (1) · Anemia, Sickle Cell (1) · Colitis, Ulcerative (1) · Crohn Disease (1) · Diabetes Mellitus (1) · Disease (1) · Endometrial Neoplasms (1) · Factor VII Deficiency (1)
Sanofi (2) · Accent Therapeutics (1) · AryoGen Pharmed Co. (1) · British Columbia Cancer Agency (1) · Columbia University (1) · Fudan University (1) · Genelux Corporation (1) · Hebei Medical University Fourth Hospital (1) · IVFarma LLC (1) · Julphar Gulf Pharmaceutical Industries (1) · Laboratorios Pisa S.A. de C.V. (1) · M.D. Anderson Cancer Center (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · Nisha Acharya (1) · Opal Rheumatology Ltd. (1)
United States (11) · France (5) · Italy (5) · Germany (4) · Spain (4) · United Kingdom (4) · Canada (3) · China (3) · Australia (2) · Belgium (2) · Netherlands (2) · South Korea (2) · Austria (1) · Czechia (1) · Hong Kong (1)
Anne-Claire Hardy-Bessard, MD (1) · Chang-Keun Lee, MD (1) · Changhoon Lee, MD (1) · Chitra Hosing (1) · Dae Hyun Yu, MD (1) · Dilorom Kamilova, PhD (1) · Eun Yeong Lee, MD (1) · Gozde Colak, PhD (1) · Gwan Gyu Song, MD (1) · Hyoun-Ah Kim, MD (1) · Hyun Ah Kim, MD (1) · Hyun-Sook Kim, MD (1)
PMID 10146588, PMID 16389894, PMID 21590439, PMID 24516013, PMID 30836953, PMID 31365335, PMID 31734899, PMID 32696266, PMID 34686353, PMID 35332298, PMID 35996930, PMID 37227734, PMID 37666539, PMID 38479822, PMID 39652449, PMID 41348038, PMID 5813452, PMID 9303355
2019 (1), 2023 (1), UG1EY038172 (1)